Efficacy and safety of weekly carfilzomib (70 mg/m

Antibodies, Monoclonal Antineoplastic Combined Chemotherapy Protocols / adverse effects Dexamethasone / therapeutic use Humans Multiple Myeloma / drug therapy Oligopeptides / adverse effects
Carfilzomib daratumumab multiple myeloma weekly regimen

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
02 2021
Historique:
pubmed: 29 10 2020
medline: 28 4 2021
entrez: 28 10 2020
Statut: ppublish

Résumé

The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m

Identifiants

DOI: 10.1080/10428194.2020.1832672 PMID: 33112184
pubmed: 33112184
doi: 10.1080/10428194.2020.1832672
doi:

Substances chimiques

Antibodies, Monoclonal 0
Oligopeptides 0
daratumumab 4Z63YK6E0E
carfilzomib 72X6E3J5AR
Dexamethasone 7S5I7G3JQL

Banques de données

ClinicalTrials.gov
['NCT03158688', 'NCT01998971']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

358-367

Auteurs

Xavier Leleu (X)

Service d'Hématologie et Thérapie cellulaire, CHU and Inserm, Poitiers, France.
ORCID: 0000-0002-9822-4170

Meral Beksac (M)

Department of Hematology, Ankara University, Ankara, Turkey.

Takaaki Chou (T)

Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.

Meletios Dimopoulos (M)

Hematology and Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
ORCID: 0000-0001-8990-3254

Sung-Soo Yoon (SS)

Department of Internal Medicine, Seoul National University, Seoul, South Korea.

H Miles Prince (HM)

Epworth Healthcare and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

Ludek Pour (L)

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.

Tatiana Shelekhova (T)

Clinic of Professional Pathology, Saratov, Russian Federation.

Ajai Chari (A)

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID: 0000-0002-0405-7480

Monica Khurana (M)

Clinical Development, Oncology, Amgen Inc., Thousand Oaks, CA, USA.

Jianqi Zhang (J)

Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA.

Mihaela Obreja (M)

Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA.

Ming Qi (M)

Hematology and Oncology, Janssen Research and Development, LLC, Spring House, PA, USA.

Albert Oriol (A)

Institut Català d'Oncologia and Josep Carreras Research Leukaemia Institute, Hospital Germans Trias i Pujol, Barcelona, Spain.

David Siegel (D)

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Efficacy and safety of weekly carfilzomib (70 mg/m
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Efficacy and safety of weekly carfilzomib (70 mg/m
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Stéroïdes fluorés › Dexaméthasone › Efficacy and safety of weekly carfilzomib (70 mg/m
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Efficacy and safety of weekly carfilzomib (70 mg/m
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › Myélome multiple › Efficacy and safety of weekly carfilzomib (70 mg/m
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Oligopeptides › Efficacy and safety of weekly carfilzomib (70 mg/m